Amundi Cuts Stock Position in Zoetis Inc. $ZTS

Amundi lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 23.6% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 2,748,011 shares of the company’s stock after selling 847,617 shares during the quarter. Amundi’s holdings in Zoetis were worth $439,038,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in ZTS. Brighton Jones LLC raised its stake in shares of Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after buying an additional 2,978 shares during the period. Atria Wealth Solutions Inc. increased its holdings in Zoetis by 23.5% in the 1st quarter. Atria Wealth Solutions Inc. now owns 17,427 shares of the company’s stock worth $2,869,000 after acquiring an additional 3,318 shares during the last quarter. Wealthspire Advisors LLC raised its stake in Zoetis by 5.1% in the 1st quarter. Wealthspire Advisors LLC now owns 6,583 shares of the company’s stock valued at $1,084,000 after acquiring an additional 318 shares during the period. Intrust Bank NA raised its stake in Zoetis by 20.2% in the 1st quarter. Intrust Bank NA now owns 1,932 shares of the company’s stock valued at $318,000 after acquiring an additional 325 shares during the period. Finally, Exencial Wealth Advisors LLC lifted its holdings in Zoetis by 27.2% during the first quarter. Exencial Wealth Advisors LLC now owns 3,117 shares of the company’s stock valued at $513,000 after purchasing an additional 667 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Zoetis stock opened at $118.69 on Friday. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. The firm has a market cap of $52.31 billion, a P/E ratio of 19.98, a P/E/G ratio of 2.50 and a beta of 0.97. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $181.85. The firm has a 50-day moving average of $133.77 and a 200-day moving average of $147.78.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. The business had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The business’s revenue was up .5% on a year-over-year basis. During the same quarter last year, the business posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 2nd. Investors of record on Friday, October 31st were issued a $0.50 dividend. The ex-dividend date was Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.7%. Zoetis’s payout ratio is 33.67%.

Analysts Set New Price Targets

ZTS has been the subject of several recent research reports. JPMorgan Chase & Co. reduced their target price on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. BTIG Research reaffirmed a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a report on Wednesday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Piper Sandler raised their target price on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Finally, UBS Group decreased their price target on Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Six equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of “Moderate Buy” and an average target price of $178.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.